With its Recursion OS at the intersection of artificial intelligence and drug discovery, a combination of computational power and life sciences that will define the next century of human industry.

Much like Palantir, Recursion is unleashing complexity, transforming biological data into something useful. 

As the next generation of AI applications emerge, Recursion Pharmaceuticals will be at the front line addressing how we tackle diseases.

Recursion’s proprietary dataset, automated screening capabilities, and ongoing partnerships with prominent companies like Exscientia, Bayer, Nvidia, Roche, Merck and more help differentiate it from others.